Biocompatibility Evaluation for Medical Devices: Where BEP, BER, TRA, and Testing Fit

What Biocompatibility Evaluation Means in Practice

For a body-contacting medical device, biological evaluation determines whether biological risks are acceptable for the finished device in its intended use. The current ISO 10993-1:2025 frames that work inside the medical-device risk-management process. It therefore starts with the device, exposure, materials, manufacturing and potential biological hazards—not with a menu of laboratory tests. The endpoint selection quick reference shows how those inputs become documented biological questions rather than automatic test orders.

FDA likewise describes assessment of the whole device in its final finished form, including sterilization where applicable, while recognizing the need to understand individual components and their interactions. Its biocompatibility basics and September 2023 final guidance are useful official starting points for US submissions. Because that guidance predates ISO 10993-1:2025, check FDA's current partial-recognition entry, exclusions, and transition details. For the EU, the same scientific evaluation must sit coherently within the general safety and performance requirements and technical documentation required by the consolidated Regulation (EU) 2017/745.

How the Main Pieces Fit Together

Where the BEP Fits

The Biological Evaluation Plan (BEP) translates intended use into an evidence plan. It should define the evaluated configuration and contact profile, identify biological hazards and relevant endpoints, review existing knowledge, explain data gaps, justify the test article, and state how each remaining question will be addressed. A good BEP also records the standards and guidance versions used so the rationale can be understood later.

Where Chemistry and TRA Fit

Chemical characterization and toxicology answer connected but different questions. ISO 10993-18:2020, including Amendment 1:2022, provides a framework to identify and, where necessary, quantify material constituents, manufacturing-introduced substances, extractables, leachables and relevant degradation products. ISO 10993-17:2023, including Amendment 1:2025, specifies the process for toxicological risk assessment of device constituents when such an assessment is required.

That relationship is especially important for polymeric devices, coatings, colourants, adhesives, residual processing chemistry, absorbable materials, or a justification that relies on chemical exposure rather than a new biological test. Chemistry is not automatically a replacement for biological evidence, and a TRA cannot repair unsuitable analytical data. The BEP should establish why the work is needed and how its result will close a defined biological-risk question.

Where Testing Fits—and Where It Does Not

Testing is appropriate when a relevant hazard remains insufficiently addressed. A cytotoxicity, sensitization, irritation, implantation or hemocompatibility study answers a defined question under defined conditions. It does not independently prove that the complete device is biologically safe, justify endpoints that were omitted, or establish that a test article represents every marketed variant.

Before a study begins, confirm the selected method, test article, extraction conditions where relevant, controls, acceptance criteria, and relationship to the intended device. FDA's test-report recommendations emphasize complete reports and justification when the specimen is not the final finished device. An otherwise valid result may be difficult to use if the article excludes a coating, bonding material, sterilization cycle, or worst-case geometry that affects exposure.

Where the BER Fits

The Biological Evaluation Report (BER) evaluates the evidence actually available and closes the planned biological-risk decisions. It should explain why each source is applicable, discuss conflicting findings and limitations, connect chemistry and toxicology where used, document residual uncertainties, and align its conclusions with the risk-management file. The BER is not the right place to discover that the wrong device was tested or that a chemistry study lacks the exposure information needed for toxicological interpretation.

A Practical Evidence Hierarchy

Do not treat every attachment as equally persuasive. Start with evidence most directly matched to the evaluated device and question:

1. Final finished-device evidence: suitable studies, characterization or clinical evidence on the current manufactured configuration, including sterilization where applicable.
2. Representative or equivalent-device evidence: data supported by a transparent comparison of formulation, processing, sterilization, geometry, contact and exposure.
3. Chemical and toxicological evidence: appropriately designed characterization linked to patient exposure and a qualified interpretation of constituent risk.
4. Published and supplier evidence: relevant literature, composition information and material history with quality, access and applicability limitations stated.
5. Clinical and post-market history: useful supportive evidence when exposure, population, surveillance quality and complaint coding are sufficiently understood.

The order is a practical guide rather than an inflexible rule. Strong evidence directly addressing a hazard can outweigh a weak nominal device match. The essential step is to document relevance instead of assuming it.

Device-Specific Examples

• Skin-contact wearable sensor: evaluate the adhesive system, wear time, repeated application, sweat and occlusion, sensor housing, colourants and any patient-contacting residue—not only the substrate.
• Externally communicating catheter: map tissue and blood contact as well as the indirect fluid path. Coatings, adhesive joints, lubricants, sterilization and duration can change endpoint and chemistry decisions.
• Permanent orthopaedic implant: integrate alloy or polymer composition, surface treatment, wear or corrosion, degradation where applicable, implantation response, long-term constituent exposure and the clinical contact site.
• Reusable instrument: consider whether repeated cleaning and sterilization alter surface condition or leave residues. The claimed end-of-life state may be the meaningful worst case rather than a new device.

Which Work Product Do You Need Next?

• Start with a BEP when the device configuration, contact classification, endpoint logic or evidence path is not yet defined.
• Commission targeted chemistry, toxicology or testing only when the plan identifies a question that existing information cannot answer.
• Prepare or remediate the BER when the evidence exists but has not been critically integrated into final conclusions.
• Use a gap review when documents already exist but the device versions, test articles, conclusions or market assumptions may not align.
• Perform a change assessment when a supplier, formulation, manufacturing step, sterilization process, packaging system, indication or exposure has changed.

Common Failure Modes

• Ordering a broad test panel before defining the biological hazards and reviewing existing data.
• Relying on a “medical grade” statement or generic polymer literature without finished-device applicability.
• Omitting indirect-contact components, additives, adhesives, process residues or sterilization effects.
• Using a predicate or previous version without a component-by-component comparison.
• Treating passing individual studies as proof that every relevant biological risk has been addressed.
• Allowing the BEP, protocols, TRA, BER and risk-management file to describe different device versions or exposure assumptions.
• Failing to define when complaints, material changes or new toxicological information require re-evaluation.

What a Review-Ready Evaluation Looks Like

A review-ready evaluation allows another qualified person to follow the reasoning from the intended finished device and clinical exposure, through biological hazards and evidence quality, to endpoint conclusions and residual risk. It distinguishes facts from assumptions, discusses uncertainty, and makes clear why any new work was necessary—or why it was not.